Merck & Co., Inc. (MRK)
| Market Cap | 199.15B |
| Revenue (ttm) | 63.92B |
| Net Income (ttm) | 17.43B |
| Shares Out | 2.51B |
| EPS (ttm) | 6.88 |
| PE Ratio | 11.53 |
| Forward PE | 8.88 |
| Dividend | $3.24 (4.09%) |
| Ex-Dividend Date | Jun 16, 2025 |
| Volume | 11,620,497 |
| Open | 80.16 |
| Previous Close | 79.96 |
| Day's Range | 78.95 - 80.31 |
| 52-Week Range | 73.31 - 128.73 |
| Beta | 0.40 |
| Analysts | Buy |
| Price Target | 112.57 (+41.94%) |
| Earnings Date | Jul 29, 2025 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for MRK stock is "Buy." The 12-month stock price target is $112.57, which is an increase of 41.94% from the latest price.
News
Merck Commits to Veeva Vault CRM
Deep application provides foundation for commercial execution PLEASANTON, Calif. , July 21, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Merck (NYSE: MRK), known as MSD outside...
July's 5 Dividend Growth Stocks With Yields Up To 7.96%
Dividend growth stocks can offer a stable way to passively grow one's income, creating long-term compounding wealth over the long run. Today, we are looking at a screening process that focuses on high...
Livestock Identification Company Evaluation Report 2025 | Merck, Shearwell, Datamars Drive Innovations with Comprehensive Tagging and Tracking Solutions
Discover comprehensive insights with the Livestock Identification Market Companies Quadrant. This analysis evaluates over 100 firms, spotlighting the Top 25 EVA Films leaders, focusing on key players,...
Merck & Co., Inc. (MRK) Presents at HIV Investor Event Transcript
Merck & Co., Inc. (NYSE:MRK) HIV Investor Event July 17, 2025 9:00 AM ET Company Participants Chirfi Guindo - Senior VP & Chief Marketing Officer of Human Health Eliav Barr - Chief Medical Officer & ...
Why Merck Is A Better Dividend Stock Than Gilead Sciences
I reiterate my Hold rating on Merck & Co., Inc. and downgrade Gilead Sciences, Inc. to Sell, as MRK outperforms on dividend growth and valuation metrics. Compared to GILD, MRK features a longer divide...
Amphista Therapeutics announces achievement of a research milestone in its collaboration with Merck triggering a milestone payment
Cambridge, UK, 16 July 2025 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery of next-generation, Targeted Protein Degradation (TPD) medicines, today announces the succe...
Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the EXPrESSIVE Phase 3 clinical trials, evaluati...
VERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc - VRNA
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Veron...
Merck's Verona Acquisition: Plugging A $4B Hole In A $20B Gap
Merck's recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent cliff. The pharmaceutical leader has made an agreement to acquire the COPD d...
FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced t...
U.S. FDA Accepts New Drug Application for Merck's Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--U.S. FDA Accepts New Drug Application for Merck's DOR/ISL Once-Daily Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1.
Measuring Options Activity in MRK & XLV: Healthcare Levels to Watch
Rick Ducat turns to the healthcare sector on today's options analysis. He starts with the SPDR Health Care ETF (XLV), noting the recent breakdown of a head and shoulders pattern and potential for both...
Major deals involving U.S. drugmakers and biotechs over the past decade
Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond its blockbuster cancer treatment Keytruda.
Undercovered Dozen: Roku, Merck, Chevron And More
The Undercovered Dozen series highlights 12 lesser-covered stocks weekly, providing investment ideas and sparking community discussion on their potential. Roku, Serve Robotics, Merck, Aeva, Chevron, I...
Merck to Buy Verona Pharma for Around $10 Billion
Merck agreed to buy respiratory drugmaker Verona Pharma for about $10 billion as it tries to make up for huge expected patent losses. Sales could fall by $18 billion over the next five years.
Merck has struck a roughly $10 billion deal to buy Verona Pharma
The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.
META Stake in Ray-Ban & Oakley Maker, MRK Acquiring VRNA, TMUS Downgrade
Meta Platforms (META) is moving to eyewear. As Diane King Hall explains, the Mag 7 giant is seeking to build its own A.I.
Merck to buy Verona for $10 billion ahead of Keytruda patent expiration
CNBC's Angelica Peebles reports on themes emerging in the pharma space.
Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug
Merck & Co. Inc. MRK agreed on Wednesday to acquire Verona Pharma plc VRNA for $107 per American Depository Share (ADS) for a total transaction value of approximately $10 billion. Each ADS represents ...
Merck dives into COPD treatments with $10 billion purchase of Verona Pharma
Verona Pharma's stock soars toward a record after $10 billion buyout deal with Merck.
Merck buys Verona for $10 billion
Evan Seigerman, BMO senior biopharma analyst, joins 'Squawk Box' to discuss Merck's decision to buy Verona, the potential impact of sector tariffs and much more.
Verona Pharma Stock Jumps 21%. It's Being Bought for $10 Billion by Merck.
The deal is expected to close in the fourth quarter of 2025.
Merck to Buy Verona Pharma in $10 Billion Deal
Merck has struck a roughly $10 billion deal to buy Verona Pharma, bolstering its lineup as it braces for the 2028 loss of patent exclusivity for the blockbuster cancer drug Keytruda.
Merck to acquire Verona Pharma for $10 billion
Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm's presence in respiratory treatments as it readies for the patent expiry of it...
Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade
RAHWAY, N.J. & RALEIGH, N.C.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical comp...